↓ Skip to main content

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

Overview of attention for article published in BMC Health Services Research, April 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
99 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand
Published in
BMC Health Services Research, April 2014
DOI 10.1186/1472-6963-14-170
Pubmed ID
Authors

Narisa Tantai, Usa Chaikledkaew, Tawesak Tanwandee, Pitsaphun Werayingyong, Yot Teerawattananon

Abstract

Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. In order to fill this gap in policy research, the objective of this study was to compare the cost-utility of each drug therapy (Figure 1) with palliative care in patients with HBeAg-positive CHB.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Belgium 1 1%
Unknown 98 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 18%
Researcher 17 17%
Student > Ph. D. Student 8 8%
Student > Bachelor 7 7%
Other 5 5%
Other 15 15%
Unknown 29 29%
Readers by discipline Count As %
Medicine and Dentistry 25 25%
Economics, Econometrics and Finance 12 12%
Nursing and Health Professions 7 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Psychology 5 5%
Other 14 14%
Unknown 30 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2015.
All research outputs
#15,299,491
of 22,753,345 outputs
Outputs from BMC Health Services Research
#5,546
of 7,617 outputs
Outputs of similar age
#133,847
of 226,967 outputs
Outputs of similar age from BMC Health Services Research
#98
of 134 outputs
Altmetric has tracked 22,753,345 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,617 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 226,967 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 134 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.